RANCHO CORDOVA, Calif.,
Oct. 14, 2019 /PRNewswire/ -- Cesca
Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell
processing and autologous cell therapies for regenerative medicine,
today announced that Jeff Cauble,
Vice President of Finance and Principal Accounting Officer, will
present at the 2019 BIO Investor Forum on Tuesday, October 22 at 4:00 pm PT. The Forum is being held October 22-23 at the Westin St. Francis Hotel in
San Francisco.
Management will also be available for one-on-one meetings with
qualified investors, analysts and interested, potential partners.
Those who would like to attend Cesca's presentation or meet with
management can register through the BIO Investor Forum website or
contact Rx Communications to schedule a meeting.
A live webcast of the presentation will be available on Cesca
Therapeutics' website
at http://investors.cescatherapeutics.com/events-and-presentations/events.
About Cesca Therapeutics Inc.
Cesca Therapeutics
develops, commercializes and markets a range of automated
technologies for CAR-T and other cell-based therapies. Its device
division, ThermoGenesis develops, commercializes and markets a full
suite of solutions for automated clinical biobanking, point-of-care
applications, and automation for immuno-oncology. The Company has
developed a semi- automated, functionally closed CAR-TXpress™
platform to streamline the manufacturing process for the emerging
CAR-T immunotherapy market. For more information about Cesca and
ThermoGenesis, please visit: www.cescatherapeutics.com.
Company Contact:
Wendy
Samford
916-858-5191
ir@thermogenesis.com
Investor Contact:
Paula
Schwartz, Rx Communications
917-322-2216
pschwartz@rxir.com
View original
content:http://www.prnewswire.com/news-releases/cesca-therapeutics-to-present-at-the-2019-bio-investor-forum-300937645.html
SOURCE Cesca Therapeutics Inc.